AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Trikafta Exercise Study in Cystic Fibrosis

Recruitingn/aAges 19 Years - anyAllUniversity of British Columbia
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene * Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit * Aged 19 years or older * Stable clinical status based on clinical judgment of the treating physician * Forced Expiratory Volume in 1 second (FEV1.0) \< 90% predicted * Body mass index greater than 16 or less than 30 kg/m\^2 * Currently non-smoking or a past smoking history of less than 20 pack-years * Able to read and understand English * Fully vaccinated (at least 2 doses) for Covid-19 Exclusion Criteria: * A disease other than CF that could importantly contribute to dyspnea or exercise limitation * Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians * Contraindications to clinical exercise testing * Use of supplemental oxygen or desaturation less than 85% with exercise * Diagnosis of pneumothorax in the past 4 weeks * History of organ transplantation
๐Ÿ’Š

What it tests

  • Trikafta
๐Ÿ“

Where

1 site
UBC Centre for Heart Lung Innovation, St. Paul's Hospital
Vancouver, Canada
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy